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The understanding of the mechanisms associated with the action of chemotherapeutic
agents is fundamental to assess and account for possible side-effects of such
treatments. Casiopeínas have demonstrated a cytotoxic effect by activation of
pro-apoptotic processes inmalignant cells. Such processes have been proved to activate
the apoptotic intrinsic route, as well as cell cycle arrest. Despite this knowledge, the
whole mechanism of action of Casiopeínas is yet to be completely understood. In this
work we implement a systems biology approach based on two pathway analysis tools
(Over-Representation Analysis and Causal Network Analysis) to observe changes in
some hallmarks of cancer, induced by this copper-based chemotherapeutic agent in
HeLa cell lines. We find that the metabolism of metal ions is exacerbated, as well as
cell division processes being globally diminished. We also show that cellular migration
and proliferation events are decreased. Moreover, the molecular mechanisms of liver
protection are increased in the cell cultures under the actions of Casiopeínas, unlike
the case in many other cytotoxic drugs. We argue that this chemotherapeutic agent
may be promising, given its protective hepatic function, concomitant with its cytotoxic
participation in the onset of apoptotic processes in malignant cells.
Keywords: causal network analysis, copper-based chemotherapy, systems pharmacology, Casiopeína II-gly, liver
protection
INTRODUCTION
From the molecular and physiological points of view, the set of pathological conditions commonly
described as cancer presents a complex phenomenology that influences the design of therapeutic
strategies. In particular, the use of anti-cancer pharmacological therapies directed at specific
molecular targets is usually considered among the best strategies to alleviate the disease. However,
due to the dense and robust network of (abnormal) interactions set-up by the biomolecular
and physiological alterations typical of cancer, the efficacy of such targeted therapies is often
challenged (de Anda-Jáuregui et al., 2015). In such cases is necessary to resort to less-specific
drugs (chemotherapeutics), whose mechanisms of action are mostly cytotoxic. Cytotoxic therapy
presents a number of disadvantages when compared with its targeted counterparts. Most cytotoxic
compounds are highly unspecific and damaging at the organismal level. For instance, metal-
based chemotherapy (such as the alkylating agent cisplatin) presents DNA damaging activity
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and induces cell death (primarily by apoptosis but also by
necrosis) in an uncontrolled way (cisplatin is a cell-cycle
unspecific drug). Long term effects in humans include anemia
and leukopenia, liver and kidney damage, neurological diseases
(such as peripheral neuropathy), serum electrolyte disturbances
and vascular toxicity among others.
Research in chemotherapy aims at developing alternative
cytotoxic agents to be used as anti-cancer drugs. Such drugs will
ideally avoid some of the most harmful side effects of current
metal-based chemotherapy. In this regard, copper-based drugs
known as Casiopeínas present a series of advantages, such as the
fact that copper-compounds may be metabolized, thus reducing
indirect toxicity andmetal-related poisoning (Ruiz-Azuara, 1997;
Bravo-Gómez et al., 2009; Valencia-Cruz et al., 2013). Aside from
this, the pharmacological dosage is lower than that of competing
therapies.
To evaluate the systemic effect of such novel cytotoxic
compounds, an integrative view is desirable since—as we already
mentioned—secondary immediate and long-term effects arise
from their use. Systems biology provides precisely such view by
incorporating elements from high-throughput omic technologies
with strong computational and analytical tools. In the past, some
systems biology attempts to study the effects of Casiopeínas
have been carried out (Gutiérrez et al., 2013; Valencia-Cruz
et al., 2013). Those efforts, however, were focused in the anti-
proliferative effects (increasing cell death and arresting cell
cycle) which are of course central to understand the main
mechanisms of antineoplastic action. Other biological processes
may, however, be affected by Casiopeínas, so that new molecular
functions—that may add to the therapeutic efficacy and possibly
to collateral effects—are expected to rise. It is desirable then,
to account for these effects in a quantitative/qualitative manner
aiming at a mechanistic characterization (Hernández-Lemus,
2013).
Genome-wide gene expression analysis (GEA) provides an
appropriate tool to study systems-level biomolecular processes
responsible for phenotypic traits. However, GEA alone falls
short represent all the complex interactions present among such
processes. For this reason, Pathway Analysis methods have been
developed to improve the predictive power derived from such
high-throughput experiments (Tarca et al., 2009; Vaske et al.,
2010; Drier et al., 2013; Krämer et al., 2013; Wang et al., 2013;
Huang et al., 2014; Verhaegh et al., 2014). Pathway level studies
have revealed new insight that may lead to a functional picture
of complex phenotypes such as the ones associated with cancer
(Lohr et al., 2012). Such methods are built upon system-level
analytics, consisting in probabilistic and computational modeling
and simulation strategies. Those strategies are performed in large
amounts of experimental data contained in carefully curated
information repositories, that may be in the form of structured
Knowledge-based data bases, but also in unstructured data-
mining and literature-search applications.
To date, a vast majority of the pathway analysis tools is based
on statistical tests on the number of differentially expressed
genes that are enlisted as part of some biological pathway.
These methods are commonly referred to as enrichment or over-
representation methods. These approaches, though very simple,
have provided an additional dimension (aimed at a functional
description) to the large scale molecular study of biological
systems. The analysis of cellular processes under the perspective
of biological interaction networks has revealed foundational
principles; these in turnmay lead to the formulation of functional
and mechanistic hypotheses to be further tested and refined.
In this regard, knowledge-based sources such as Ingenuity
Knowledge-Base (IKB, Krämer et al., 2013) present an effective
alternative (based on highly curated information sources, relying
on detailed experimental evidence and extensive literature
references) to large scale probabilistic and computational
modeling, especially useful when facing small sample counts, as
is the case here.
MATERIALS AND METHODS
Synthesis of Casiopeína II gly
Copper complexes, Casiopeína II-gly (Cas II-gly), were
synthesized by starting with an equimolar solution of copper
(II) nitrate mixed together with the corresponding substituted
diimine (in this case, glycine), followed by the addition of a
N-O donor previously deprotonated, as previously reported
(Bravo-Gómez et al., 2009). Infrared (IR) spectrum analysis
followed synthesis and the product was compliant with a
previous characterization (Ruiz-Azuara, 1997).
Cell Line Cultures
The HeLa cell line (American Type Culture Collection, CCL-2;
Rockville, MD, USA) was maintained at 37◦C in 5% CO2 under
sterile conditions in Dulbecco’s modified Eagle medium (DMEM,
Sigma Chemical Co., St Louis, MO, USA) supplemented with
10% fetal bovine serum (Sigma) and treated for 6 h with IC50 of
Cas II-gly (40µM) in 96 microplates (Valencia-Cruz et al., 2013).
Cells were stained with sulphorrodamine-B and absorbance
was quantified in a spectrophotometer at 560 nm (Lab-system
Uniskan, Manchester, UK).
Cellular Viability
Cellular viability was estimated by the 3-(4,5-dimethythiazol-
2y1)-2,5-diphenyl-tetrazolium bromide (MTT) assay (Roche
Diagnostics, Mannheim, Germany). Briefly, cells (2 × 105 per
well) were seeded in 24-well culture plates and preincubated for
24 h. After exposure to treatment for 24 h at 37◦C, 2ml of MTT
(0.1mg/ml) was added, and cells were then incubated for 3 h at
37◦C in darkness. The tetrazolium crystals were solubilized by
the addition of 10% SDS in 0.01 N HCl, and the formazan blue
formed from MTT was quantified with a spectrophotometer at
560 nm (Lab-system, Uniskan, Manchester, UK).
RNA Extraction and Preparation
In order to extract RNA, HeLa cells (5 × 106 cells) treated or
not with 40µM Cas II-gly for 6 h were collected in 1ml of
Trizol (Invitrogen) and extraction was performed according to
manufacturer’s instructions. RNA integrity was determined by
means of gel electrophoresis, and nucleic acid concentration
was measured with a spectrophotometer (Amersham Pharmacia
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Biotech). Reverse transcription was performed with Superscript
II Reverse Transcriptase (Invitrogen, No. cat.18064-014) and
cDNA was amplified with Taq DNA Polymerase (Invitrogen,
No. cat. 11615-010). PolyA+ RNA from HeLa cells were
selected by affinity chromatography using an oligo (dT) cellulose
column.
Genome-Wide Microarray Gene
Expression Analysis
Genome wide gene expression experiments were performed in
a set of double-triplicates for cases (treatment with Cas II-
gly) and controls. Total mRNA was extracted from the two
sets of cells and processes under the GPL570 protocol in
Affymetrix HGU133Plus2 arrays (Valencia-Cruz et al., 2013).
Gene expression data has been publicly archived at NCBI GEO
under accession key GSE41827. Additional information can be
also found as a NCBI BioProject with Accession PRJNA178551
and ID 178551.
Pathway Enrichment Analysis
Web-GESTALT (Wang et al., 2013) enrichment tool is focused
mainly in the identification of over-represented pathways with
the rationale that the proportion of differential expressed genes,
within a given pathway, exceeds the proportion of genes that
could be randomly expected (Garcia-Campos et al., 2015).
Pathway enrichment was performed in order to uncover enriched
pathways compliant with the set of differentially expressed genes
obtained by comparing the HeLa cell lines treated with Cas-
II gly vs. a control group. Web-GESTALT is a comprehensive
large scale data-mining webtool. It covers 78,612 functional
categories over a dozen of large scale public databases. It
performs statistical enrichment over the full set of annotated
pathways and calculates statistical significance by means of FDR-
corrected hypergeometric tests. In the work presented here, we
used a corrected p-value threshold of 10−4.
Causal Network Analysis
In order to validate and complement the results obtained by
the pathway enrichment analysis, a causal network analysis was
performed. The Ingenuity Pathway Analysis toolkit (IPA R©,
QIAGEN Redwood City, www.qiagen.com/ingenuity) was then
used to generate Causal Networks (Krämer et al., 2013). IPA
depends on a highly curated knowledge-based archive known
as the IKB. IKB integrates data from more than 40,000 nodes
representing mammalian genes and their products (transcripts,
proteins, miRNAs, second messengers, etc.) in addition to
chemical compounds (both exogenous and endogenous). IKB
archives more than 1,480,000 interactions between molecules.
Such interactions conform the set of links between the
nodes which represent experimentally observed cause-effect
relationships (hence the name, Causal Networks) relative to
transcription, expression, activation, molecular modification,
binding events, and transport processes. These interactions have
been experimentally measured, so they can be associated with a
definite direction of the causal effect—activation or inhibition—
of the given processes at a whole genome network-wide
level.
IKB data is highly-curated since inference procedures are
based in two independent sources: First, enrichment scores
are determined by hypergeometric tests or Fisher’s exact
tests—depending on the statistical dependency conditions on
the variables under consideration—that measure the overlap
between observed and predicted gene sets. Second, IPA calculates
Z-scores to evaluate the match between observed and predicted
up/down regulation patterns allowing for Bayesian scoring of
the results (Krämer et al., 2013). As we mentioned above, gene
expression data has been publicly archived at NCBI GEO under
accession key GSE41827. For the causal network analysis we used
these same data. To consider a differentially expressed gene in
this analysis, we used a log Fold Change (LFC) of 1.5 and a
corrected p-value of 10−4. The pipeline followed to perform this
work is depicted in Figure 1.
Overall Picture
Taking into account the aforementioned heterogeneous nature
of cancer and the promising action of Cas II-gly in other
systems, it results important to understand more general
mechanisms of action of these chemotherapeutics from the
FIGURE 1 | Pipeline depicting the data/information workflow for this
study.
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point of view of systems biology. In this work, we focused on
pathway analysis—based on our previously publishedmicroarray
expression data from HeLa cell lines—to observe the signaling
pathways that become overexpressed and underexpressed after
the action of Cas II-gly, in order to broaden our knowledge
of the effect of copper-based therapies. We found that the
mechanisms activated by the action of Cas II-gly are related to
metal ion response, transcription factor networks, and immune
system pathways. On the other hand, the inhibited pathways
are related to cell cycle progression, transformation of cells
and migration. An important feature that appears to be a
consequence of the chemotherapeutic is that some molecules
involved in liver protection are overexpressed, suggesting an
hepatoprotective action of Cas II-gly. With this approach we
remark the necessity of experimental procedures that confirm the
results obtained here.
RESULTS
Effects on General Biological Processes
In Figure 2, the main pathways affected by treatment with
Cas II-gly in HeLa cell lines are depicted in the form of a
heatmap. Looking at the general features of the overexpressed
(red) and underexpressed (green) pathways, we can observe that
the processes that are upregulated are mostly related to oncogene
pathways (names colored in red in the Figure 2), immune system
(blue), signal transduction (green), and transcription factor
networks (black). These results indicate that treatment with Cas
II-gly could be activating immune response and cell repairing
mechanisms in the treated cells. On the other hand, several
biological processes which are downregulated are involved in cell
cycle (turquoise) as well as cell division; furthermore, several
processes related to cellular structural maintenance are also
underexpressed (gold labels). This could be indicative of a
decrease in the mechanisms of proliferation. Both responses
are, in some sense, to be expected after chemotherapeutic
action.
In the case of Gene Ontology, taking into account the
overexpressed genes of the HeLa cells with Cas II-gly treatment,
we observe the following: the majority of enriched categories
in the Biological Process branch are related to apoptotic
processes (Figure 3). Concomitantly with this, there is a branch
of processes involved in the response to metal ions. This is
consistent with the fact that Cas II-gly is a copper-based therapy
and then, the cellular mechanisms to metabolize metal ions are
thus activated.
If we look at the underexpressed genes (Figure 4), the
enriched categories (p < 10−5) of GO Biological Process
are related to mitosis and regulation of the transcription
processes. Again, this indicates a diminishing of the mitotic and
transcriptional events in the Cas II-gly treated cell lines, a positive
outcome of the systemic effect of Cas II-gly, as compared with
platinum-based cytotoxic drugs.
Effects on Cell Cycle Regulation
Regarding the regulatory effects of cell cycle processes, causal
network analysis shows the following results:
Cas II-gly Inhibits Estrogen-Mediated Cell Cycle
Progression
Figure 5 shows the IKB estrogen-mediated signaling S-phase
entry pathway. Molecules depicted in green are underexpressed,
whereas overexpressed molecules are represented in red. White
molecules are not differentially expressed (at the chosen level
of statistical significance) with respect to the untreated group.
It is clear that the majority of differentially expressed molecules
are underexpressed, which indicates a considerable depletion of
the process. It is remarkable that estrogen is not differentially
expressed; the activation of the pathway could however be
triggered via a cross-talk event, in which estrogen downstream
molecules could be inhibited by messengers belonging to other
pathways. Due to these crosstalk events, the expression level
of the estrogen-receptor (ER) may not determine the resulting
effect on the pathway, since other components of this pathway
could be modulated by any other crosstalking pathways. For
instance, in de Anda-Jáuregui et al. (2015), it is shown that
the estrogen signaling pathway (ESP) might be affected via
the apoptosis signaling pathway in breast cancer samples;
this result is consistent with previous experiment of crosstalk
between apoptosis and ESP (Clarke et al., 2012; Cook et al.,
2014).
Cas II-gly Downregulates Transformation Processes
in Fibroblasts
An upstream regulator analysis from IPA knowledge base, shows
that FOXM1 and NTRK2 control the processes of proliferation
of fibroblasts, being these effects proportional to their expression
level. The lower the expression level in those molecules, the
lower the activity of those events. These two molecules promote
the activity of several other participants in the regulation
of fibroblast cell cycle and transformation: CDC25, CDKN1A,
etc. (Figure 6). It is worth to mention that transformation of
fibroblasts is a crucial step in tumor progression since these cells
are involved in the formation of extracellular matrix (ECM).
Another feature of fibroblast function is their role in mitotic
process induced by cellular damage. Thus, downregulation of this
process contributes to decrease malignant effects such as tumor
growth, invasiveness or vascularization.
Cas II-gly Treatment Reduces Cell
Migration in HeLa Cell Lines
It is already known that MED1, TGFBR1 and DKK1
underexpression decreases migration of cells, (Larsson et al.,
2001; Ohlmann et al., 2010; Cui et al., 2012; Li et al., 2013). In
the IPA knowledge base analysis it is shown that those molecules
are underexpressed which in turn diminish the migration of
cells (Figure 7). Again, the effect of Cas II-gly results in the
inhibition of a very well-known hallmark of cancer: uncontrolled
cell migration (Hanahan and Weinberg, 2000, 2011). The
result presented here is another instance of the lowering of cell
migration by the action of a cytotoxic agent.
Effects on Liver Injury and Protection
One of the most evident and undesirable side effects of
chemotherapy is the one related to hepatotoxicity (Kufe et al.,
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FIGURE 2 | Heatmap of the main pathways affected by treatment of HeLa Cells with Cas II-gly. Color gradient corresponds to the − log [corrected p− value]
of the hypergeometric test performed for the pathway enrichment analysis for a p = 10−4. Overexpressed pathways are shown in red, whereas the underexpressed
ones are shown in green. The names of the pathways are colored according to the category which they belong to: oncogene pathways (red), immune system (blue),
signal transduction (green), transcription factor networks (black), cell cycle and cell division (turquoise), and cellular structure maintenance (gold names). Please notice
that the most general features of the overexpressed pathways are related to oncogene pathways, immune response, signal transduction, and transcription factor
networks. Meanwhile the underexpressed pathways are related to cell cycle, cell division and cell structure maintenance.
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FIGURE 3 | Statistically enriched GO Biological processes enriched in overexpressed genes in Cas II-gly treated HeLa cells vs. controls. Statistically
significant GO:terms are shown in red (p < 10−5). It results interesting the fact that the enriched processes with the overexpressed genes are those related to
apoptosis and metal ion cellular response.
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FIGURE 4 | Statistically enriched GO Biological processes enriched in underexpressed genes in Cas II-gly treated HeLa cells vs. controls. The enriched
processes of the deepest levels are involved in cell division and regulation of transcription.
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FIGURE 5 | Causal network depicting the inhibitory effect of Cas II gly on estrogen-mediated G1/S cell cycle progression. Molecules depicted in green
are underexpressed in the whole genome microarray gene expression analysis. Red arrows indicate activation and the blue ones represent inhibition. The original
network is provided as a Figure S1.
2003; Koschny et al., 2007), since it affects at organismal level
and very often is even more harmful than the tumor itself. In
this regard, we examined the effect of Cas II-gly treatment on the
liver damage pathway inHeLa cell lines.We obtained a promising
result: The mechanisms of protection to the liver are activated
and the damage of liver tissue mechanisms are also arrested
(Figure 8).
It is worth to mention that there are several findings
that support this assertion: For instance, in Wang et al.
(2011) it is shown that IL6 decreases injury of liver. Since
this protein is overexpressed in our HeLa samples, we can
argue that this mechanism could be present under exposure
of Cas II-gly. Furthermore, Jund depletion increases injury
of liver (Marden et al., 2008). Due to the fact that Jund is
overexpressed in our samples, this could also be indicative that
there is another mechanism of liver protection. Participation
of MAPK14 could be relevant in the context of liver
protection. This molecule is not differentially expressed in
our samples, however, its target molecules were differentially
expressed.
Another instance of molecules related to mechanisms of liver
protection is heme-oxygenase 1, HMOX1. Quite remarkably,
HMOX1 protects liver in several forms (Seki and Brenner,
2008; Sass et al., 2012). Moreover, HMOX1 is the third most
overexpressed gene in our samples (Table 1); hence, to argue that
this molecule is importantly influencing the mechanisms of liver
protection is reasonable. Li et al. (2009) demonstrate that knock-
out mice of Scd1 gene increase liver damage. Overexpression of
this molecule in our samples could be indicative of other liver
protecting mechanisms.
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FIGURE 6 | Causal network depicting the inhibitory effect of Cas II-gly on the cell cycle progression of fibroblasts and their transformation processes.
This figure was obtained by using the regulator effects tool in the Ingenuity platform. Blue symbols indicate a predicted inhibition of the associated process.
Orange symbols (not shown here) represent a predicted activation. Green molecules symbolize underexpression in the case versus the control samples. Analogously,
red-pink molecules represent overexpression. It can be observed that the four processes in the bottom part are clearly downregulated, indicating another instance of
the effect that Cas II-gly exerts on the arrest of the cell cycle. The original figure, containing all molecules and associated processes, is provided as Figure S2. For
clarity, we removed those molecules and arrows which are not directly linked to those processes.
DISCUSSION
Cancer is a complex disease, with a plethora of intricate
mechanisms that determine the features of specific phenotypes
which in turn give place to distinct prognosis and treatment.
Chemotherapy is one of the most used treatments to face
this condition. Casiopeínas have shown an important
chemotherapeutic effect on cancer cell lines (Valencia-Cruz et al.,
2013). The intrinsic route to apoptosis is favored by caspase-3
activation via cyt C overexpression, high ROS concentrations, as
well as cell cycle arrest; whereas the extrinsic route to apoptosis is
somehow diminished due to very low expression of procaspase-8
and caspase-8. Antiapoptotic processes are switched-down,
due to low levels of Bcl-2. Furthermore, copper-based therapy
could be more convenient than other cytotoxic agents in terms
of a decrease in side effects, since copper, being an essential
trace element can be metabolized. Casiopeínas reach the
membrane of mitochondria and exerts a pro-apoptotic effect
(Valencia-Cruz et al., 2013), as can be seen in Figure 3. As
it was previously mentioned, Cas II-gly activates molecules
that participate in oxidative stress processes and reduces cell
viability by the intrinsic apoptotic pathway. In this work, we
developed an integrative systems biology approach to elucidate
the effect of Cas II-gly treatment in HeLa cell lines, observing
new features, namely, inhibition of G1/S transition phase,
decrease of cell transformation process and a decrease of cell
migration.
Cas II-gly promotes apoptosis and metal ion signaling
responses (Valencia-Cruz et al., 2013). At the same time, with
the results shown by this analysis, we demonstrate that Cas II-gly
inhibits cell proliferation, cell migration, transformation of cells
as well as cell cycle progression in HeLa cell lines. Furthermore,
this treatment promotes the liver repairing system as well as the
activation of molecules related to decrease of liver damage.
Regarding the inhibitory effect that Cas II-gly has on cell
cycle and transcription, it can be observed in Figures 5–7,
that the inducer molecules involved in those processes are
underexpressed. A good example of this is depicted in Figure 5,
where a considerable subset of the molecules involved in the
estrogen-mediated G1/S phase progression are underexpressed.
A similar effect is observed in Figure 6, where the upstream
molecules FOXM1 and NTRK2 are downregulated. This
downregulation event affects the cell-division molecules
CDC25A, CCND1, CCNE1, MYC, SKP2, and CCNA2.
Interestingly, FOXM1 underexpression abolishes the negative
feedback with CDKN1A (Wang et al., 2002, 2007); this cyclin-
dependent kinase inhibits the S-phase entry of fibroblasts (Sherr
and Roberts, 1999). It is worth to mention that, despite the
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FIGURE 7 | Causal network depicting the effect inhibitory of Cas II-gly on cell migration processes. The color code is the same than the previous figure.
Notice that several molecules in the figure are underexpressed and those molecules, being underexpressed, their activator role is dampened. At the same time,
overexpressed molecules CDKN1A and HMOX1 inhibit the migration process. As in the previous figure, the original one is provided as Figure S3.
FIGURE 8 | Causal network depicting the effect of Cas II-gly on liver injury and protection. Please notice how the activating arrows are decreasing the effect
of liver damage, thus indicating that Cas II-gly treatment exerts a hepatoprotective effect. The original figure obtained by the regulator effect tool of Ingenuity
platform is provided as Figure S4.
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TABLE 1 | Top20 of differentially expressed genes in HeLa cell lines under
the effect of Cas II-gly.
Ratio ID Entrez gene name
6.92 HSPA6 Heat shock 70kDa protein 6 (HSP70B′)
4.41 IL8 Chemokine (C-X-C motif) ligand 8
4.16 HMOX1 Heme oxygenase 1
4.1 MAFF V-maf avian musculoaponeurotic fibrosarcoma
oncogene homolog F
3.74 ATF3 Activating transcription factor 3
3.09 SLC30A1 Solute carrier family 30 (zinc transporter), member 1
2.94 GADD45B Growth arrest and DNA-damage-inducible, beta
2.75 C11orf96 Chromosome 11 open reading frame 96
2.54 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1
2.53 ERRFI1 ERBB receptor feedback inhibitor 1
−2.41 C14orf104 Dynein, axonemal, assembly factor 2
−2.43 GEMIN4 Gem (nuclear organelle) associated protein 4
−2.49 SKP2 S-phase kinase-associated protein 2, E3 ubiquitin
protein ligase
−2.51 FZD2 Frizzled class receptor 2
−2.66 FADD Fas (TNFRSF6)-associated via death domain
−2.66 GAS1 Growth arrest-specific 1
−2.67 FBXO5 F-box protein 5
−2.73 MYO10 Myosin X
−3.2 MYC V-myc avian myelocytomatosis viral oncogene
homolog
−3.52 DKK1 Dickkopf WNT signaling pathway inhibitor 1
fact that the network depicted in Figure 6 corresponds to
processes diminished in fibroblasts and bone cancer cell lines,
the molecules involved in these processes are ubiquitous in all
cell types. Furthermore, some of these molecules are known to
be markers of tumor growth as well as cell cycle progression. As
it was explained before, Ingenuity Pathway Analysis contains
a large database of interactions. Those interactions have been
highly curated by literature or ex professo experiments. The
observed processes of Figure 6 correspond to interactions of
those molecules observed on those cell types. However, the
interactions are also common in many other cell types. Based on
that, to extrapolate the effects that Cas-II gly exerts on fibroblasts
to HeLa cell lines may be appropriate in terms of the set of
molecules implied in those processes.
By observing Figure 7, it can be noticed that MED1 exerts
a repression on CDKN1A (p21) which in turn inhibits cell
migration (Lee et al., 2013); the same is true of HMOX1
(Lu et al., 2012); thus, concomitant overexpression of these
molecules exert a negative role in migration. Other molecules
involved in the process of cell migration are underexpressed;
all of those molecules have a pro-migration role. Hence, their
underexpression generates a global anti-migration effect. This
could be relevant in terms of the complementary role that
Casiopeínas may have as a therapeutic treatment: Casiopeínas act
as a cytotoxic (Bravo-Gómez et al., 2009; Gutiérrez et al., 2013;
Valencia-Cruz et al., 2013) and concomitantly they may exert an
inhibitory effect on cell migration.
In this work, we have performed pathway analysis with two
different but complementary strategies. The general mechanism
of action of Cas II-gly is known in terms of the damage to DNA
and mitochondrial stress. However, the whole set of different
effects that this drug exerts on the cell is not well-known. With
the analysis performed here, we observe that somemolecules that
have been related to liver damage and repairing are differentially
expressed in the treated cells respecting the control ones. These
molecules are ubiquitous in any cell type: JUND, IL6, HMOX1,
ADM, MAPK14, DDT3. The importance of these results lies
on the fact that these molecules are consistently associated with
protection from hepatic damage (at the systemic level). The
experiment shown here, was performed in a cervical cancer cell
line. However, the effect of Cas II-gly in this cell line activates
(or deactivates) specific molecules that have been observed to
perform a particular effect at the systemic level. It remains to
be tested (by means of in vitro but even more importantly, by
in vivo models and clinical experiments) whether the molecular
pathways activated by Cas II-gly are actually able to induce such
liver protecting processes in living subjects.
Cas II-gly is a potent and promising chemotherapy. In this
regard, the results presented here corroborate the potential usage
of this drug as an anticancer therapy. One of the most relevant
results is related to liver damage. In Figure 8 can be observed
that almost every molecule in the figure is overexpressed, and
these molecules inhibit liver damage. Activation of molecules
downstream of MAP2K3 allows a protection of the liver, with
the exception of p21 (CDKN1A). The overall effect of those
interactions is hepatoprotective. The last result might be helpful
in terms of the clinical potential, given the fact that themajority of
metal ion therapy is based on platinum, and it is also well-known
that platinum cannot be naturally metabolized. Furthermore, the
GO (biological processes) terms in the overexpressed genes sets
are enriched for the response of the metal ion signaling pathway,
reflecting the fact that cells are facing to this external agent.
Further steps toward a complete understanding of the
mechanisms of action of Casiopeínas, involve a comparative
analysis in vivo. Experiments in this regard are currently on
their way. Such analyses, as well as a toxicological study
(phase I clinical trial) in human subjects are ongoing within
our group. In the meantime, the systems biology approach
presented here, shows general and also specific features of the
regulatory effect that Cas II-gly may exert, and this knowledge
could be relevant to provide a more integrated overview of
the processes in which novel anticancer therapies are involved,
looking for the understanding of global chemotherapeutic
mechanisms.
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